About CHC 2022
Join us for the 12th annual Canadian Hematology Conference (Virtual)
on September 30th – October 1st
CHC 2022 was held on a virtual streaming platform, running September 30th – October 1st.
CHC is the largest multi-disciplinary hematological conference across Canada. It brings together a pan-Canadian and International Faculty to showcase cutting-edge research and developments in the field of hematology.
Dr. John Kuruvilla (Princess Margaret Cancer Centre) and Dr. Peter Anglin (Stronach Regional Cancer Centre) will co-chair this event. CHC 2022 is open to Canadian hematology professionals, including residents, nurses, pharmacists, and specialists who have an interest in hematology.
Register to gain access to:
- Leading clinical presentations
- Panelist discussions / Q&A
- First access to clinical slide decks
- Year-round access to recorded CHC 2022 presentations
Access the CHC 2022 Report
for Videos on-Demand!
Featuring: Speaker Bios, Presentations, Q&As, Powerpoints
Event Chairs
Dr. John Kuruvilla
Princess Margaret Cancer Centre
Dr. Peter Anglin
Stronach Regional Cancer Centre
Agenda
Presentations and timing follow:
Day 01
September 30th 2022 | 9:00AM–6:00PM [EST]
9:00 — Opening Remarks
9:05 — Aggressive B-cell Lymphoma
Frontline Therapy [ + Q&A ]
Dr. Laurie Sehn, BCCA, Vancouver
Second Line (And Beyond) [ + Q&A ]
Dr. Michael Crump, PMCC, Toronto
10:21 — Break
10:36 — Indolent (Follicular and Mantle Cell) Lymphoma
Managing patients with Relapsed/Refractory Follicular Lymphoma [ + Q&A ]
Dr. Gilles Salles, Memorial Sloan Kettering, NY
Recent Advances in the Management of Mantle Cell Lymphoma [ + Q&A ]
Dr. Diego Villa, BCCA, Vancouver
Advances in BiTE Therapy for Lymphoma [ + Q&A ]
Rob Laister PhD, PMCC, Toronto
12:32 — Lunch Break
13:00 — Hodgkin Lymphoma
Approaches in Frontline Advanced Hodgkin Lymphoma
[ + Q&A ]
Dr. Alison Moskowitz, Memorial Sloan Kettering, New York
Primary Treatment of Localized Hodgkin Lymphoma
Dr. John Kuruvilla, PMCC, Toronto
Hodgkin Lymphoma: Future Directions in Treatment
Dr. Stephen Ansell, Mayo Clinic, Rochester, MN
14:31 — Break
14:45 — Plasma Cell Dyscrasias
Newly Diagnosed Multiple Myeloma [ + Q&A ]
Dr. Keith Stewart, PMCC, Toronto
Multiple Myeloma – Relapsed Disease [ + Q&A ]
Dr. Rafael Fonseca, Mayo Clinic, Arizona
New Agents in Multiple Myeloma
Dr. Paola Neri, Arnie Charbonneau Cancer Institute, Calgary
16:27 — Break
16:40 — Myeloid Leukemia
AML: The Evolving Landscape of Frontline Therapy
a. intensive induction
b. non-intensive induction
Dr. Guillaume Richard-Carpentier, PMCC, Toronto
17:58 — Closing Remarks
Day 02
October 1st 2022 | 9:00AM–1:00PM [EST]
9:00 — Opening Remarks
9:05 — Chronic Lymphocytic Leukemia
Frontline CLL Treatment [ + Q&A ]
Dr. Stephan Stilgenbauer, Ulm University, Germany
Management of CLL in the Relapsed Setting: a Canadian Perspective [ + Q&A ]
Dr. Versha Banerji, CancerCare Manitoba, Winnipeg
10:15 — CLL Supplementary Symposium
BTK Inhibitors in CLL: Current standards of care and emerging data
Dr. Jennifer Brown, Dana-Farber Cancer Institute, Boston
10:54 — Break
[Postponed] — Challenges in Hematology in Canada
Cancer Care for Indigenous People
Tobi Mitchell, Director of Health – Chiefs of Ontario
11:10 — Recap of last two days
Key pearls and highlights
13:10 — Closing Remarks
Sponsors
GOLD
SILVER
BRONZE
